Back to Search

ERNEST BORDEN, MD

MD

Medical Oncology Physician

NPI: 1740243716Individual

Specialties, Licenses & Credentials

Medical Oncology PhysicianPrimary

Internal Medicine — Medical Oncology

Code: 207RX0202X

35075789B(OH)

Research & Publications (20)

Melanoma 2007: current state and preview of the future.
PMID 18083367·Semin Oncol·2007
8-other
Adult sarcomas: a missed opportunity for sustained cooperative group translational and clinical research.
PMID 17396485·Oncology (Williston Park)·2007
6-review
Interferons at age 50: past, current and future impact on biomedicine.
PMID 18049472·Nat Rev Drug Discov·2007
6-review
Review: Milstein Award lecture: interferons and cancer: where from here?
PMID 16181052·J Interferon Cytokine Res·2005
7-preclinical
Soft tissue sarcomas of adults: state of the translational science.
PMID 12796356·Clin Cancer Res·2003
6-review
Reducing primary melanoma mortality.
PMID 11122855·Curr Oncol Rep·2000
6-review
Melanoma and pregnancy.
PMID 11130472·Semin Oncol·2000
8-other
Second-generation interferons for cancer: clinical targets.
PMID 10936063·Semin Cancer Biol·2000
6-review
Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.
PMID 19514839·J Interferon Cytokine Res·2009
7-preclinical
Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro.
PMID 18937547·J Interferon Cytokine Res·2008
7-preclinical
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
PMID 18235122·J Clin Oncol·2008
3-trial
Apoptosis: a clinical perspective.
PMID 19065702·Nat Rev Drug Discov·2008
8-other
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
PMID 18955451·J Clin Oncol·2008
3-trial
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
PMID 18006112·Lung Cancer·2008
3-trial
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
PMID 17653094·Oncogene·2008
8-other
Intimal pulmonary artery sarcoma presenting as dyspnea: case report.
PMID 17603895·Int Semin Surg Oncol·2007
8-other
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
PMID 17339865·Clin Pharmacol Ther·2007
3-trial
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
PMID 17557954·J Clin Oncol·2007
3-trial
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.
PMID 17823654·J Clin Invest·2007
8-other
Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.
PMID 17103170·Cancer Chemother Pharmacol·2007
7-preclinical

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
9500 EUCLID AVE
CLEVELAND, OH 44195

Location

Practice Location

9500 EUCLID AVE, CLEVELAND, OH
(800) 223-2273

Quick Facts

NPI
1740243716
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
20

Are you this provider?

Claim Your Profile